GALLIUM: GAZYVA vs rituximab product Is the Largest 1L FL Study Ever Conducted

This Phase III, open-label, randomized trial was designed to answer one primary question: In patients with previously untreated FL, did the GAZYVA (obinutuzumab) based regimen deliver superior PFS compared with the rituximab product-based regimen? 1

The GALLIUM trial studied patients with previously untreated follicular lymphoma (Grades 1-3a, stage III/IV or stage II bulky disease [≥7 cm])

  • Primary endpoint: PFS as assessed by Independent Review Committee (IRC)
  • Additional endpoint: Response rates at end of induction (IRC-assessed, assessed by CT)

BULKY DISEASE AND ADVANCED STAGING PREVALENT AT BASELINE 1,6

The GAZYVA and rituximab product arms were generally well balanced with respect to demographic factors and baseline disease characteristics 6

GALLIUM evaluated GAZYVA vs rituximab product when each was combined with bendamustine, CHOP, or CVP and followed by GAZYVA or rituximab product monotherapy, respectively